Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cell Pathways Holdings (NasdaqNM:CLPA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
702 Electronic Drive
Horsham, PA 19044
Phone: (215) 706-3800
Fax: (215) 706-3801
Email: investor@cellpathways.com
Employees (last reported count): 60
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 23%
·Institutional: 19% (25% of float)
(99 institutions)
·Net Inst. Selling: 3,000  shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cell Pathways Holdings (CPI) is a development-stage pharmaceutical company focused on the research, development and commercialization of products to prevent and treat cancer. The Company's technology is based upon the discovery of a novel mechanism that, based on the Company's research, can be targeted to induce selective apoptosis in pre-cancerous and cancerous cells (neoplastic cells) without affecting apoptosis in normal cells. Apoptosis is a naturally occurring physiological process wherein a number of components inside a cell program the cell to die without causing harm to surrounding cells. The Company has created a new class of selective apoptotic anti-neoplastic drugs (SAANDs) and has synthesized many new chemical compounds in this new class. In screening assays, many of these new compounds have displayed greater apoptotic potency than the Company's lead drug candidate, Aptosyn (exisulind).
More from Market Guide: Expanded Business Description

Financial Summary
Cell Pathways Holdings is a pharmaceutical company focused on the research, development and commercialization of products to prevent and treat cancer. For the six months ended 6/30/01, revenues totaled $317 thousand vs. no revenue. Net loss fell 30% to $9.6 million. Revenues reflect the agreement with Aventis Pharmaceuticals for marketing Nilandron. Lower loss also reflects the reductions in the purchase of raw materials for Aptosym and decreased marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Robert Towarnicki, 49
Chairman, Pres, CEO
$280K--  
Brian Hayden, 49
CFO, VP-Fin., Treasurer
190K$2.1M
Rifat Pamukcu, M.D., 43
Exec. VP, Director, and CSO
212K--  
Martha Manning, 46
Sr. VP, Gen. Counsel, Sec.
--  --  
Robert Bellet, M.D., 58
Sr. VP, Clinical and Regulatory Affairs
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CLPAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Dec-2000
$3.25 
Recent Price$5.66 
52-Week High
on 1-Sep-2000
$34.50 
Beta1.22 
Daily Volume (3-month avg)88.0K
Daily Volume (10-day avg)81.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-83.2%
52-Week Change
relative to S&P500
-77.4%
Share-Related Items
Market Capitalization$176.1M
Shares Outstanding31.1M
Float24.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.26 
Earnings (ttm)-$0.77 
Earnings (mrq)-$0.16 
Sales (ttm)$0.02 
Cash (mrq)$1.24 
Valuation Ratios
Price/Book (mrq)4.48 
Price/EarningsN/A 
Price/Sales (ttm)261.80 
Income Statements
Sales (ttm)$647.0K
EBITDA (ttm)-$24.7M
Income available to common (ttm)-$22.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-51.72%
Return on Equity (ttm)-57.56%
Financial Strength
Current Ratio (mrq)12.99 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$38.5M
Short Interest
As of 8-Aug-2001
Shares Short4.55M
Percent of Float18.9%
Shares Short
(Prior Month)
4.51M
Short Ratio63.17 
Daily Volume72.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.